Tier 1 newswirebarrons.com
U.S. Treasury Wants to Rein In Deals for Chinese Biotech and AI
The U.S. Treasury's move to impose restrictions on investments related to Chinese biotech and AI marks a significant escalation in the de-risking approach toward China, predominantly affecting capital flows and cross-border mergers and acquisitions. This development poses a threat to U.S. pharmaceutical companies that rely on innovative partnerships and technologies from China, especially given the potential for breakthroughs in cancer treatment. The current geopolitical landscape underlines the urgency of these measures, further bolstering structural demand for the USD as companies seek to repatriate capital amid increasing regulatory scrutiny.